Elanix
Route de Champ Colin, 18
Nyon
1260
Tel: 41-22-552-09-71
Website: https://elanixbiotechnologies.com/
Email: tomas.svoboda@elanix.ch
About Elanix
Elanix is a Swiss Life Science company dedicated to regenerative medicine using progenitor cells stored and expanded in its own GMP validated Master Cell Bank. Elanix is the sole owner of a set of skin progenitor cell lines that can be further multiplied generating over 35 billion of 10×10 cm advanced wound dressings without any further cell technology related costs. Elanix has the option to license to two patents invented by the founder during the tenure as a professor in the University Hospital of Lausanne, Switzerland (CHUV).YEAR FOUNDED:
1994
LEADERSHIP:
Founder and CSO: Lee Ann Laurent-Applegate
CEO: Tomas J. Svoboda
JOBS:
Please click here for Elanix Biotechnologies job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
7 articles about Elanix
-
Elanix Launches Adherence App For Gynrepair Women’s Intimate Health Cream
6/27/2017
-
Elanix Starts EU Commercialization Of Gynrepair Cream For Women’s Intimate Relief
5/31/2017
-
Elanix Signs Agreement With Apraxon To Establish European Logistics Center
4/21/2017
-
Elanix Acquires Third Cell Based Bioactive Cream Formulation With Potential To Alleviate A Significant Chronic Dermatological Condition
3/16/2017
-
Elanix Announces Non-Binding Letter Of Intent With Oxford MEstar Ltd. In Regard To Setting Up A JV To Market GynRepair In China
11/22/2016
-
Elanix Technologies Strategic Partner, Transwell Biotechnology, Receives U.S. FDA Clearance For Phase I/II Clinical Trial Using Fibroblast Progenitors TWB-103
11/8/2016
-
Elanix Technologies Signs Supply And Manufacturing Agreements With Sincopharm And Tec-Pharma For Production Of Medical Cosmetics Acquired From Repair-A
10/10/2016